• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biomed Res Int . Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes

tetano

Editor, Senior Moderator
Biomed Res Int


. 2022 May 10;2022:2350063.
doi: 10.1155/2022/2350063. eCollection 2022.
Epidemiology of COVID-19 in Tehran, Iran: A Cohort Study of Clinical Profile, Risk Factors, and Outcomes


Hamidreza Hatamabadi[SUP] 1 [/SUP], Tahereh Sabaghian[SUP] 2 [/SUP], Amir Sadeghi[SUP] 3 [/SUP], Kamran Heidari[SUP] 4 [/SUP], Seyed Amir Ahmad Safavi-Naini[SUP] 5 [/SUP], Mehdi Azizmohammad Looha[SUP] 6 [/SUP], Nazanin Taraghikhah[SUP] 3 [/SUP], Shayesteh Khalili[SUP] 7 [/SUP], Keivan Karrabi[SUP] 8 [/SUP], Afsaneh Saffarian[SUP] 9 [/SUP], Saba Shahsavan[SUP] 5 [/SUP], Hossein Majlesi[SUP] 5 [/SUP], Amirreza Allahgholipour Komleh[SUP] 10 [/SUP], Saba Hatari[SUP] 5 [/SUP], Nadia Zameni[SUP] 5 [/SUP], Saba Ilkhani[SUP] 5 [/SUP], Shideh Moftakhari Hajimirzaei[SUP] 5 [/SUP], Aydin Ghaffari[SUP] 5 [/SUP], Mohammad Mahdi Fallah[SUP] 5 [/SUP], Reyhaneh Kalantar[SUP] 5 [/SUP], Nariman Naderi[SUP] 5 [/SUP], Parnian Bahmaei[SUP] 5 [/SUP], Naghmeh Asadimanesh[SUP] 5 [/SUP], Romina Esbati[SUP] 5 [/SUP], Omid Yazdani[SUP] 5 [/SUP], Fatemeh Shojaeian[SUP] 5 [/SUP], Zahra Azizan[SUP] 5 [/SUP], Nastaran Ebrahimi[SUP] 5 [/SUP], Fateme Jafarzade[SUP] 5 [/SUP], Amirali Soheili[SUP] 11 [/SUP], Fatemeh Gholampoor[SUP] 5 [/SUP], Negarsadat Namazi[SUP] 5 [/SUP], Ali Solhpour[SUP] 12 [/SUP], Tannaz Jamialahamdi[SUP] 13 [/SUP], Mohamad Amin Pourhoseingholi[SUP] 6 [/SUP], Amirhossein Sahebkar[SUP] 14 15 16 [/SUP]



Affiliations

Abstract

Background: The outbreak of coronavirus disease 2019 (COVID-19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR.
Methods: This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran's National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID-19.
Results: Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID-19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51.
Conclusions: Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.
 
Back
Top Bottom